Erythropoietin and chronic lymphocytic leukemia

Reviews in Clinical and Experimental Hematology

Volumn 6, Issue SUPPL. 1, 2002, Pages 21-31

  Mauro, Francesca R ^a   Gentile, Massimo ^a   Foa, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYANOCOBALAMIN; CYTOKINE; ERYTHROPOIETIN; FOLIC ACID; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT ERYTHROPOIETIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW; BONE MARROW SUPPRESSION; BURST FORMING UNIT E; CANCER INFILTRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; COLONY FORMING UNIT E; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; HUMAN; HYPERSPLENISM; LYMPHOPROLIFERATIVE DISEASE; NUTRITIONAL DISORDER; PROGNOSIS; QUALITY OF LIFE; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LEUKEMIA; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ERYTHROPOIESIS; MULTICENTER STUDY; PATHOLOGY; PURE RED CELL ANEMIA; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANEMIA; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTINEOPLASTIC AGENTS; BONE MARROW; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIESIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSPLENISM; LEUKEMIA, B-CELL, CHRONIC; LYMPHOPROLIFERATIVE DISORDERS; MULTICENTER STUDIES; NUTRITION DISORDERS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; RED-CELL APLASIA, PURE; TREATMENT OUTCOME;

EID: 0036046172     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Erythropoietin production in anemia associated with experimental cancer
2. Chemotherapy-induced anemia in adults: Incidence and treatment
3. Erythropoietin and the anemia of cancer
4. Anemia of cancer
5. Erythropoietin and the anemia of chronic disease
6. Decreased erythropoietin response in patients with the anemia of cancer
7. Serum erythropoietin and reticulocyte counts in inflammatory process
8. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias
9. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon
10. Inhibition of human colony-forming units by tumor necrosis factor requires beta interferon
11. Tumor necrosis factor (TNF)-α directly inhibits human erythropoiesis in vitro: Role of p55 and p75 TNF receptors
12. The anemia of chronic disorders
13. Anemia of chronic disease
14. Interaction of inflammatory cytokines and erythropoietin in iron metabolism and erythropoiesis in anaemia of chronic disease
15. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo
16. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients
17. Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy
18. Factors associated with platinum-induced anemia in ovarian cancer (OVCA) patients (pts) in Southwest Oncology Group (S) studies
19. The frequency of the red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study
20. An epidemiological review of anaemia in cancer chemotherapy in Canada
21. Patterns of bone marrow involvement in chronic lymphocytic leukemia and small lymphocytic (well differentiated) non-Hodgkin's lymphoma. Its clinical significance in relation to their differential diagnosis and prognosis
22. Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy
23. Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia
24. Autoimmunity in chronic lymphocytic leukaemia
25. Incidence and prognostic significance of autoantibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL)
26. Leucemia linfatica cronica B: Anemias hemoliticas autoimmunes versus anemias debidas a un fallo medular
27. Chronic lymphocytic leukemia: Clinical studies based on 189 cases followed for a long time
28. Case/control study of the role of splenectomy in chronic lymphocytic leukemia
29. Accessory cells, cytokine loops and cell-to-cell interactions in chronic lymphocytic leukaemia
30. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production
31. The role of interleukin 1, erythropoietin, and red cell bound immunoglobulins in the anaemia of rheumatoid arthritis
32. Chronic lymphocytic leukaemia associated with myelodysplastic syndrome and/or chronic myeloid leukemia: Evidence for independent clonal chromosomal evolution
33. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia
34. Clinical staging of chronic lymphocytic leukemia
35. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
36. A clinical staging system for chronic lymphocytic leukaemia. Prognostic significance
37. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: Clinical, therapeutic, and prognostic features
38. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: A single institution study of 204 cases
39. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
40. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial
41. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: A German multicenter phase II study
42. Treatment of refractory chronic lymphocytic leukemia with Fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: Five-year follow-up report
43. Erythropoietin treatment of anemia associated with multiple myeloma
44. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response
45. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study
46. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma
47. Clinical and health status assessments in anaemic chronic lymphocytic leukaemia (CLL) patients treated with epoetin alfa
48. Effective treatment of disease-related anaemia in B chronic lymphocytic leukemia patients with recombinant human erythropoietin
49. Combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) for the treatment of advanced non-responsive chronic lymphocytic leukemia
50. Correction of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: Maintenance is necessary to sustain response
51. "downstaging" Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin
52. Serum erythropoietin in chronic lymphocytic leukaemia
53. Responsiveness to recombinant human erythropoietin (rh-Epo) of marrow erythropoietin progenitors (CFU-E and BFU-E) from B-chronic lymphocytic leukemia (B-CLL)
54. Pharmacokinetics and pharmacodynamics of epoietin alfa once weekly and three times weekly
55. Clinical evaluation of once-weekly dosing of epoietin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
56. Development and characterization of novel erythropoiesis stimulating protein (NESP)
57. Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half-life (t1/2) in oncology patients (pts)
58. Novel erythropoiesis stimulating protein